Recent Updates
Recently added Catalysts
SNTI Positive Sentiment

NOT gate gene circuits expand the range of tumor-associated antigens addressable by CAR-NK and -T cell therapies

Tuesday, October 31, 2023 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses advancements in NOT gate gene circuits that broaden the spectrum of tumor-associated antigens targeted by CAR-NK and CAR-T cell therapies. This innovative approach was highlighted at the SITC Annual Meeting, showcasing its potential to enhance cancer treatment efficacy. The research involves contributions from multiple experts in the field.
Price reaction · baseline $2.798 (2023-10-31 close) · hit after-hours · 3 other SNTI headline(s) in the window, move may be shared
day 0 close · peak
+3.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • Innovative approach to expand tumor-associated antigens
  • Potential to enhance CAR-NK and -T cell therapies
  • Promising developments presented at SITC Annual Meeting

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+84%
120-day peak, hindsight
Typical move
76.7%
average across 4 past catalysts
Cash runway
~5 mo
High dilution risk
Lead asset
SENTI-202
Phase 1 · AML/MDS

Full Press Release Details

SITC Annual Meeting Nicholas W. Frankel, Assen Roguev, Marcus Gainer, Han Deng, Priscilla Wong, Gozde Yucel, Alice Lam, Yongshuai Li, Michelle Hung, Derrick Lee, Chen-Ting Lee, Andrew Banicki, Mengxi Tian, Niran Almudhfar, Wenqi Song, Lawrence Naitmazi, Brian Garrison, Kanya Rajangam, Timothy K. Lu

Frequently Asked Questions

What are NOT gate gene circuits?

NOT gate gene circuits are innovative tools that expand the range of tumor-associated antigens.

How do NOT gate circuits impact CAR-NK therapies?

They enhance CAR-NK therapies by broadening the spectrum of targetable tumor antigens.

Where were these findings presented?

The findings were presented at the SITC Annual Meeting.

Who contributed to this research?

The research involved multiple experts, including Nicholas W. Frankel and others.

ShareAdd on Google
Tags: SNTI Viatris Investor Conferences Healthcare CAR-NK CAR-T tumor antigens SITC Annual Meeting
Last updated: Oct 31, 2023

Biotech snapshot

Cash runway
$19M liquidity · $2M/mo burn
~5 mo
High dilution risk
Lead asset
SENTI-202Phase 1
AML/MDS →

Catalyst track record

+84%
best trade around SNTI's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for SNTI.

See every catalyst's timing & PoA →